Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Curevac

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Curevac. Displaying page 1 of 1.
    EudraCT Number: 2008-007785-39 Sponsor Protocol Number: CV-9201-003 Start Date*: 2009-04-20
    Sponsor Name:CureVac GmbH
    Full Title: Safety and efficacy phase I/IIa trial of an RNActive®-derived cancer vaccine in stage IIIB/IV non small cell lung cancer (NSCLC)
    Medical condition: It will be conducted in stage IIIB/IV NSCLC cancer patients with documented stable disease or objective response according to RECIST criteria after initial chemotherapy or chemo-radiotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004489-32 Sponsor Protocol Number: CV-9104-007 Start Date*: 2014-03-05
    Sponsor Name:CureVac AG
    Full Title: An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer
    Medical condition: prostate carcinoma (intermediate and high risk)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10036921 Prostate carcinoma LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004070-22 Sponsor Protocol Number: CV-NCOV-003 Start Date*: 2021-04-12
    Sponsor Name:CureVac AG
    Full Title: COVID-19: A Phase 3 multicenter clinical trial to evaluate the safety, reactogenicity and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in adults 18 years of age and above wi...
    Medical condition: Vaccination for prophylaxis of COVID-19 (adults with co morbidities)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004066-19 Sponsor Protocol Number: CV-NCOV-005 Start Date*: 2020-12-18
    Sponsor Name:CureVac AG
    Full Title: COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care ...
    Medical condition: Vaccination for prophylaxis of COVID-19 (healthy adults)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003998-22 Sponsor Protocol Number: CV-NCOV-004 Start Date*: 2020-12-16
    Sponsor Name:CureVac AG
    Full Title: COVID-19: A Phase 2b/3, Randomized, Observer-Blinded, Placebo Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 1...
    Medical condition: Vaccination for prophylaxis of COVID-19 (healthy adults)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084464 COVID-19 immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-006314-14 Sponsor Protocol Number: CV-9104-004 Start Date*: 2012-07-10
    Sponsor Name:CureVac AG
    Full Title: A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory P...
    Medical condition: Metastatic Castrate-refractory Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003967-37 Sponsor Protocol Number: CV-9103-001 Start Date*: 2008-12-08
    Sponsor Name:CureVac GmbH
    Full Title: Safety and efficacy trial of a RNActive®-derived prostate cancer vaccine in hormone refractory disease
    Medical condition: patients with hormone-refractory prostate cancer (HRPC) with rising PSA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10062904 Hormone-refractory prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003389-10 Sponsor Protocol Number: HepaVac-101 Start Date*: 2017-03-29
    Sponsor Name:Istituto Nazionale Tumori G. "Pascale"
    Full Title: A phase I/II trial of IMA970A plus CV8102 following a single pre-vaccination infusion of cyclophosphamide in patients with very early, early and intermediate stage of hepatocellular carcinoma after...
    Medical condition: Very early, early and intermediate stage hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 02 22:36:25 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA